Limit Use of Unproven Outpatient Treatments for COVID-19

February 2021

We’re hearing about lots of oral “cocktails” to treat COVID-19 in outpatients...with azithromycin, dexamethasone, ivermectin, etc.

It’s tempting to try to repurpose affordable, relatively safe meds...grasping for something to help.

Currently the only authorized options for outpatients are the monoclonal antibodies bamlanivimab or casirivimab/imdevimab...given as IV infusions to those at high risk of serious COVID-19 complications.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote